BioNTech SE
Explore BioNTech
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
3 leaders · Full leadership timeline
BioNTech was founded to use the immune system against cancer, then became globally famous through Comirnaty. The company is now trying to convert the credibility and cash from that vaccine success into a multi-product oncology business.
BioNTech makes money through COVID-19 vaccine collaboration revenue, partner milestones, development collaborations, service businesses, and eventual product commercialization. Its future business model depends on turning immuno-oncology candidates into approved products.
Chief Executive Officer and Co-Founder
Sahin founded BioNTech and continues to lead the company through its oncology pivot while preparing to transition by the end of 2026.
Chief Medical Officer and Co-Founder
Tureci shapes BioNTech's clinical strategy and is also expected to transition to a new independent mRNA company by the end of 2026.
Chief Financial Officer
Zapata oversees BioNTech's financial discipline and cash deployment during the high-investment oncology pivot.
BioNTech faces normalized COVID vaccine demand, high R&D expense, complex oncology trials, partner execution risk, and a planned founder leadership transition by the end of 2026.
Prof. Ugur Sahin, M.D. is Chief Executive Officer and co-founder of BioNTech; the company has announced a planned founder transition by the end of 2026.
Ugur Sahin's priority is advancing BioNTech's oncology pipeline while preparing a smooth leadership transition by the end of 2026.
BioNTech's leadership includes scientific co-founders, a management board, and newer executives focused on people, finance, operations, and commercial readiness.
BioNTech competes by using mRNA science, immuno-oncology platforms, partnerships, and a large cash balance to build a multi-product oncology company after the COVID vaccine boom.
The leadership risk is transition timing: the company must keep scientific momentum while replacing founder leadership roles by the end of 2026.